Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Drixine - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Drixine

Approved

STANDARD

Drixine

Famar Montreal Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: b627421b8ca8b316
Company: Famar Montreal Inc.
Type: Standard

Approval Details

Approval Id: b627421b8ca8b316
Drug Approval Philippines Name: Drixine
Product Name: Drixine
Registration Number: DR-XY46699
Brand Name: Drixine
Generic Name: Oxymetazoline Hydrochloride
Dosage Form: Nasal Spray
Dosage Strength: 500mcg/mL (0.05%)
Manufacturer: Famar Montreal Inc.
Importer: Bayer Philippines, Inc.
Distributor: Bayer Philippines, Inc.
Issuance Date: 24 May 2023
Expiry Date: 12 September 2026
Pharmacologic Category: Nasal Decongestant
Classification: Over-The-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

b627421b8ca8b316

Type

Standard

Back to Philippines FDA Approvals